ARCHIVES

New benchmark for CCSG award funding will be lowered from 20 percent of NCI research base to 15 percent, the program’s “reality ratio,” Karen Antman tells NCAB.

This article is from The Cancer Letter archive.

Vol. 30 No. 38 | October 8, 2004

Download PDF Visit The Full Archive

Related Articles

FDA Approves Iressa For Third-Line Treatment Of Non-Small Cell Lung Cancer

May 9, 2003

Reaction To PSA Guideline Muffled Compared to 2009 Mammography Guideline

October 14, 2011

Letters to the Editor: Burzynski: Reviewers Sought To Discredit Antineoplaston Therapy

October 30, 1998

DRCA Planning Described; New Cancer Control Conference Set

February 4, 1983

GAO Report Finds Hydrazine Sulfate Trials Were Accurate

September 29, 1995

Group Urges U.S., USSR Exchange In Surgical Oncology

January 6, 1989